A Study of the Availability of Medicines for the Treatment of Hiv-Infected Patients in the Republic of Bashkortostan

Abstract

According to the order of the Government of the Russian Federation of 01.12.2004 № 715 the disease caused by the virus of immunodeficiency of the person enter the list of socially significant diseases and the list of the diseases presenting danger to people around. Therefore, the aim of the research was to study the dynamics of the volume of procurement of medicines for the treatment of HIV-infected patients and the assortment availability of antiretroviral medicines in the Republic of Bashkortostan. The studies were conducted during the period of 2010–2016 years. The objects were the materials of reporting of the State Budget Health Agency Republican Center for Prevention and Control of AIDS and infectious diseases, electronic cards of government contracts. Methods of research: statistical, marketing, logic-economic, ATC/DDDs. The average growth rate in procurement of antiretroviral medicines is relatively the basic 2010 in monetary terms amounted to 168,52%. The largest share (1⁄2 part) were domestic medicines with one active substance. In value terms, there is a significant reduction of 26,74% in the volume of purchases of imported medicines with one active substance. At the same time, the import antiretroviral medicines were more in demand among combined antiretroviral medicines: their share increased by 28,56%. In natural terms, the share of domestic medicines with one active substance increased by 49,37%, in general, the share of the volume of antiretroviral medicines purchases of domestic production increased by 2,64 times. An analysis was conducted of the levels of management of assortment based on the calculation of the coefficients of the latitude of ARVs, regional mesocontours of domestic and imported ARVs of the six of the analyzed ATCgroups 4-th level were formed. The number of average daily doses of DDDs/1000 people/day for ARVs was calculated. It is established that the dominating in 2010–2016 there were ARVs of two ATC-subgroups: non-nucleoside — reverse transcriptase inhibitors (NNRTIs) and Nucleoside — reverse transcriptase inhibitors (NRTIs), which corresponds to the preferred first-line regimen for patients who had not previously taken antiretroviral therapy.